In an affront to the scientific method, a judge in NJ recently ruled that a terminally ill teenager with muscular dystrophy should be allowed to use an experimental drug treatment despite objections from the drug’s developer. In a era where validity of these scientific trials are being questioned, one has to wonder how this ruling will effect the future of medication research. These studies are set up in advance with strict inclusion guidelines to make sure the results are statistically significant. You can't just add a patient on a whim no matter how much it tugs at your heart strings. The risk of ruining the whole experiment is too high.
“We’re very pleased with what has happened,” said Marc E. Wolin, a lawyer for the Gunvalson family. “This was the relief that we sought. It’s a big step in the right direction.”
Big step in the right direction for whom? Does one patient outweigh the benefits of many patients? Call me a maverick but I don't think lawyers and judges should decide who gets on a study. This may open to floodgates for other lawyers to do the same thing which will end up destroying many of the ongoing studies throughout the country.